Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Decrease in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 33,421 shares, a drop of 58.4% from the May 14th total of 80,248 shares. Based on an average trading volume of 57,636 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Guggenheim raised their target price on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. UBS Group raised their target price on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, Leerink Partners raised their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NBTX. Royal Bank of Canada raised its stake in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Optiver Holding B.V. acquired a new position in Nanobiotix in the 3rd quarter valued at about $101,000. Marshall Wace LLP acquired a new position in Nanobiotix in the 4th quarter valued at about $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix in the 4th quarter valued at about $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Stock Up 5.3%

NASDAQ:NBTX opened at $35.33 on Friday. Nanobiotix has a 52-week low of $4.18 and a 52-week high of $57.14. The stock has a fifty day simple moving average of $37.60 and a 200-day simple moving average of $29.36.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $3.42 million during the quarter. As a group, research analysts predict that Nanobiotix will post 0.19 EPS for the current year.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.